Data from the health ministry of India has revealed that the country's vaccination campaign has slowed despite amassing record stock of COVID-19 vaccines, Reuters news agency reported on Monday.
This comes as authorities maintain a wider-than-usual gap between doses in a strategy that has boosted coverage.
The gap, exceeding the eight to 12 weeks recommended by the World Health Organisation, has reportedly allowed India to give at least one vaccine dose to 74% of its 944 million adults, with just 30% getting the full complement of two.
Domestic production of the AstraZeneca (LON:AZN) COVID-19 vaccine, which accounts for nearly 90% of administered doses, has more than tripled since May 2021, when a supply shortage prompted India to double the period between doses to between 12 and 16 weeks.
The AstraZeneca vaccine, known as Covishield, accounts for 861 million doses of India's total injected figure of 977.6 million, while its other main vaccine, Covaxin has a dose interval of four to six weeks.
Health ministry figures indicate that over the last few days, daily stocks of all COVID-19 vaccines have exceeded 100 million doses for states and federally controlled territories taken together.
In contrast, daily vaccinations have dropped to an average of five million doses this month and even less in the past week, off a daily peak of 25 million last month.
According to the ministry, it followed recommendations from a group of experts in making any changes to dosage, arrived at by weighing up "scientific and empirical" evidence.
Pfizer reports positive Phase 3 data for ABRYSVO in adults at risk for RSV disease
Clover Bio announces SCB-1019 vaccine candidate Phase I trial data in initial young adult cohort
Sanofi launches Verorab for rabies prophylaxis in UK
BioVaxys expands patent portfolio for DPX delivery platform and advances DPX SurMAGE
YS Biopharma repays USD40m loan facility
Kintara Therapeutics and TuHURA Biosciences to merge
VGXI names new chief accounting officer
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Valneva launches Phase 1 trial for next-generation Zika vaccine
Circio Holding ASA confirms licensing deal with IOVaxis Therapeutics in China and Singapore
Everest Medicines names new chief medical officer and chief product officer
Pfizer's PREVENAR 20 gains European Commission approval for paediatric pneumococcal vaccine